Skip to main content
Navigate Up
Sign In

Combination Treatment Targets Pre-Leukemia Stem Cells

“Current treatments for MDS [myelodysplastic syndrome] are not designed to specifically target the malignant stem cells. This makes treatment much like mowing over weeds without killing the root. Patients can achieve some benefit from chemotherapy, but eventually the MDS stem cells drive progression of the disease,” says Craig T. Jordan, investigator at CU Cancer Center, Chief of the Division of Hematology and the Nancy Carroll Allen Professor of Hematology at the CU School of Medicine.